|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0017355,
umls-concept:C0025914,
umls-concept:C0026809,
umls-concept:C0033578,
umls-concept:C0086418,
umls-concept:C0456387,
umls-concept:C0567416,
umls-concept:C1171362,
umls-concept:C1515670,
umls-concept:C2936626
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-8-25
|
|
pubmed:abstractText |
There has been a determined search for therapies specifically aimed at eradicating tumor cells while leaving normal host cells unaffected. This goal can potentially be accomplished by engaging tumor antigen-specific T-cell repertoire to attack the tumor. A pre-requisite for a successful T-cell-mediated attack against tumors or pathogens is that the target tissues express major histocompatibility complex (MHC) molecules. Using newer anti-MHC class I and MHC class II antibody reagents, we re-examined the expression of MHC in both human and mouse prostate tumors and their microenvironments.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-10079295,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-10395109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-10501850,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-10657015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-11137210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-11431355,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-11479621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-12198549,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-15573129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-15824085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-1691655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-1954898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-2085409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-2178696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-2436753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-6167639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-7495121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-7585572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-7606778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-7690428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-7724580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-8011283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-8293464,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-8305680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-8368769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-8797572,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9051144,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9285591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9397194,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9457311,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9485029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16741922-9822272
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0270-4137
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2006 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1275-84
|
|
pubmed:dateRevised |
2011-8-1
|
|
pubmed:meshHeading |
pubmed-meshheading:16741922-Aged,
pubmed-meshheading:16741922-Animals,
pubmed-meshheading:16741922-Antigens, CD3,
pubmed-meshheading:16741922-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16741922-Histocompatibility Antigens Class I,
pubmed-meshheading:16741922-Histocompatibility Antigens Class II,
pubmed-meshheading:16741922-Humans,
pubmed-meshheading:16741922-Immunohistochemistry,
pubmed-meshheading:16741922-Male,
pubmed-meshheading:16741922-Mice,
pubmed-meshheading:16741922-Mice, Transgenic,
pubmed-meshheading:16741922-Middle Aged,
pubmed-meshheading:16741922-Neoplasm Staging,
pubmed-meshheading:16741922-Prostatic Neoplasms
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.
|
|
pubmed:affiliation |
Department of Microbiology, Georgetown University Medical Center, Washington, District of Columbia, USA. nandan@niaid.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
